Holen Sie sich die Stockscreener-App
0.239
6.57%
-0.0168
Handel nachbörslich:
.24
0.001
+0.42%
Schlusskurs vom Vortag:
$0.2558
Offen:
$0.2474
24-Stunden-Volumen:
23.10M
Relative Volume:
2.57
Marktkapitalisierung:
$42.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.89M
KGV:
-0.0945
EPS:
-2.53
Netto-Cashflow:
$-11.95M
1W Leistung:
-16.20%
1M Leistung:
-58.79%
6M Leistung:
-54.89%
1J Leistung:
-80.57%
1-Tages-Spanne:
$0.2203
$0.2483
1-Wochen-Bereich:
$0.2203
$0.318
52-Wochen-Spanne:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Vergleichen Sie PSTV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.239 | 45.63M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Published on: 2026-01-27 09:16:26 - baoquankhu1.vn
Institution Moves: Is Plus Therapeutics Inc on track to beat earningsTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Price Action: Is Euroholdings Ltd. stock showing strong momentumJuly 2025 Recap & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1.5 - 富途牛牛
Plus Therapeutics secures $5.7M to support leptomeningeal metastases program - MSN
H.C. Wainwright Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Cuts Target Price to $1 - 富途牛牛
H.C. Wainwright lowers Plus Therapeutics stock price target on equity offering - Investing.com
Plus Therapeutics (PSTV) Sees Price Target Cut by HC Wainwright - GuruFocus
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics By Investing.com - Investing.com South Africa
Aug Mood: Is ABCL forming higher highs and higher lowsJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - baoquankhu1.vn
Market Review: What dividend growth rate does Plus Therapeutics Inc offerWeekly Gains Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. Provides Business Update on REYOBIQ Clinical Program and U.S. CNSide Commercialization - marketscreener.com
PSTV: $15M raise funds clinical and commercial growth; CNSIDE targets break-even by 2027 - TradingView — Track All Markets
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET - Sahm
Plus Therapeutics Sets 2026 Milestones For REYOBIQ Clinical Program And CNSide Commercial Rollout - Nasdaq
Plus Therapeutics outlines 2026 goals for cancer treatments and diagnostics - Investing.com
PSTV Analyst Rating Update: Price Target Lowered to $4.00 | PSTV Stock News - GuruFocus
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy - TipRanks
PSTV: 2026 focus: CNSide scale-up, REYOBIQ pivotal trial prep, and expanded payor coverage - TradingView
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization - manilatimes.net
Plus Therapeutics plans CNS cancer test coverage for 150M US lives - Stock Titan
Plus Therapeutics, Inc. Updates Corporate Presentation on Cancer Radiotherapeutics - TradingView
Plus Therapeutics To Provide Business Update Today As Radiotherapeutic Pipeline Advances - Nasdaq
Plus Therapeutics To Provide Business Update On Thursday - TradingView
Plus Therapeutics, Inc. to Host Business Update and Conference Call on January 22, 2026 - Quiver Quantitative
Plus Therapeutics to Provide Business Update and Host - GlobeNewswire
Should you avoid Plus Therapeutics Inc stock right now2025 Winners & Losers & Verified Momentum Stock Alerts - baoquankhu1.vn
Earnings Report: Will Plus Therapeutics Inc benefit from rising consumer demand2025 Market Overview & Stock Portfolio Risk Management - baoquankhu1.vn
Growth Value: Is Plus Therapeutics Inc a cyclical or defensive stockMarket Movement Recap & AI Enhanced Execution Alerts - baoquankhu1.vn
Aug Opening: Can Plus Therapeutics Inc reach all time highs this yearLayoff News & Real-Time Volume Triggers - baoquankhu1.vn
Plus Therapeutics completes underwritten public equity offering - TipRanks
Plus Therapeutics Signs Underwriting Agreement With Lake Street Capital Markets - TradingView — Track All Markets
Plus Therapeutics Inc enters underwriting agreement with Lake Street Capital Markets, LLCSEC filing - marketscreener.com
Plus Therapeutics IncOn Jan 13, Co Enters Underwriting Agreement With Lake Street Capital Markets, LlcSEC Filing - TradingView — Track All Markets
Whale Trades: Is UONE stock suitable for long term investingJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
Analyst Downgrade: Is UDR Inc in accumulation or distribution phaseJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering - Sahm
Plus Therapeutics prices $15 million public offering at $0.38 per unit - Investing.com Nigeria
Plus Therapeutics Prices Public Offering, Raising $15 Million - Intellectia AI
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance - Nasdaq
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - MSN
Plus Therapeutics stock plunges after pricing $15M units offering - MSN
Plus Therapeutics (PSTV) Shares Plummet After $15M Unit Offering - GuruFocus
Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges - Benzinga
PSTV Plunges On $15 Mln Upsized Offering - Nasdaq
Plus Therapeutics (PSTV) Launches $15M Public Offering - GuruFocus
Plus Therapeutics announces pricing of upsized $15 million public offering - marketscreener.com
Plus Therapeutics Announces Pricing Of Upsized $15 Million Public Offering - TradingView — Track All Markets
CNS cancer-focused company raises $15M in stock and warrant sale - Stock Titan
Dow Update: Can Plus Therapeutics Inc reach all time highs this yearQuarterly Trade Summary & AI Enhanced Execution Alerts - baoquankhu1.vn
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):